Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...

Its medical name is “urticaria.” Hives can be acute (temporary) or chronic (ongoing). The condition is typically characterized by itchy, welts on the skin. Xolair is used to treat chronic ...

A young British woman suffers from an extremely rare allergy to water, which keeps her away from taking a shower or cleaning ...

Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU ... CSU – also known as chronic hives—compared the drug to a placebo.

Medically reviewed by Daniel More, MD Hives (urticaria) are a common skin reaction that causes bumps, raised patches, or both. They are one way the body responds to an allergen or trigger. Reactions ...

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU ... also known as chronic hives. Xolair (omalizumab) has been around ...

but can now point to a win for rilzabrutinib in chronic spontaneous urticaria (CSU). In a phase 2 trial, rilzabrutinib has been shown to rapidly reduce itch severity and significantly improve ...

What if the food you eat and the way you handle stress could make a real difference for your chronic spontaneous urticaria?

for a drug designed to treat the skin condition known as chronic spontaneous urticaria, or chronic hives. But on Monday, Allakos announced that the tests flopped — and that the company is now ...